专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2006012451A3 COMPOSITIONS AND METHODS OF USE FOR MGD-CSF IN DISEASE TREATMENT 审中-公开
标题翻译： MGD-CSF在疾病治疗中的组合物和使用方法
公开(公告)号：WO2006012451A3
公开(公告)日：2006-03-30
申请号：PCT/US2005025941
申请日：2005-07-21
申请人： FIVE PRIME THERAPEUTICS INC , BEHRENS DIRK , BOSCH ELIZABETH , DOBERSTEIN STEVEN , HALENBECK ROBERT FORGAN , HESTIR KEVIN , HUANG MIN MEI , LEE ERNESTINE , LIN HAISHAN , LINNEMANN THOMAS , MARSHALL SHANNON , WONG JUSTIN G P , WU GE , ZHOU AILEEN
发明人： BEHRENS DIRK , BOSCH ELIZABETH , DOBERSTEIN STEVEN , HALENBECK ROBERT FORGAN , HESTIR KEVIN , HUANG MIN MEI , LEE ERNESTINE , LIN HAISHAN , LINNEMANN THOMAS , MARSHALL SHANNON , WONG JUSTIN G P , WU GE , ZHOU AILEEN
IPC分类号： C12N15/27 , C07K14/53 , C07K16/18 , C12N5/10 , C12Q1/68 , G01N33/68
CPC分类号： C07K16/243 , A61K38/00 , C07K14/53
摘要： Disclosed is a newly identified secreted molecule, identified herein as "monocyte, granulocyte, and dendritic cell colony stimulating factor" (MGD-CSF), the polypeptide sequence, and polynucleotides encoding the polypeptide sequence. Also provided is a procedure for producing the polypeptide by recombinant techniques employing, for example, vectors and host cells. Additionally, procedures are described to modify the disclosed novel molecules of the invention to prepare fusion molecules. Also disclosed are methods for using the polypeptides and active fragments thereof for treatment of a variety of diseases, including, for example, cancer, autoimmune and inflammatory diseases, infectious diseases, and recurrent pregnancy loss.
摘要翻译：公开了一种新鉴定的分泌型分子，本文称为“单核细胞，粒细胞和树突状细胞集落刺激因子”（MGD-CSF），多肽序列和编码多肽序列的多核苷酸。还提供了通过使用例如载体和宿主细胞的重组技术产生多肽的方法。另外，描述了修饰所公开的本发明新颖分子以制备融合分子的方法。还公开了将多肽及其活性片段用于治疗各种疾病，包括例如癌症，自身免疫性和炎性疾病，感染性疾病和复发性怀孕损失的方法。

2. 发明申请

WO2004038003A3 HUMAN POLYPEPTIDES ENCODED BY POLYNUCLEOTIDES AND METHODS OF THEIR USE 审中-公开
标题翻译：多核苷酸编码的人多肽及其使用方法
公开(公告)号：WO2004038003A3
公开(公告)日：2004-12-09
申请号：PCT/US0333947
申请日：2003-10-24
申请人： FIVE PRIME THERAPEUTICS INC , WILLIAMS LEWIS T , CHU KETING , LEE ERNESTINE , HESTIR KEVIN , BEAURANG PIERRE ALVARO , BEHRENS DIRK , HALENBECK ROBERT FORGAN , KOTHAKOTA SRINIVAS , LIN HAISHAN , LINNEMANN THOMAS , PIERCE KRISTEN , WANG YAN , WONG JUSTIN G P , WU GE , ZHANG HONGBING , ZENG CHANGJIANG
发明人： WILLIAMS LEWIS T , CHU KETING , LEE ERNESTINE , HESTIR KEVIN , BEAURANG PIERRE ALVARO , BEHRENS DIRK , HALENBECK ROBERT FORGAN , KOTHAKOTA SRINIVAS , LIN HAISHAN , LINNEMANN THOMAS , PIERCE KRISTEN , WANG YAN , WONG JUSTIN G P , WU GE , ZHANG HONGBING , ZENG CHANGJIANG
IPC分类号： A61K38/00 , A61K39/395 , A61K48/00 , C07K14/00 , C07K14/47 , C07K16/00 , C12N20060101 , C12N5/10 , C12N15/11 , C12N15/63 , G01N33/53
CPC分类号： C07K14/47
摘要： The invention provides novel polynucleotides, related polypeptides related nucleic acid and polypeptide compositions, and related modulators, such as antibodies and small molecule modulators. The invention also provides methods to make and use these polynucleotides, polypeptides, related compositions, and modulators. These methods include diagnostic, prophylactic and therapeutic applications. The compositions and methods of the invention are useful in treating proliferative disorders, e.g., cancers, and inflammatory, immune, bacterial, and viral disorders.
摘要翻译：本发明提供了新颖的多核苷酸，相关的多肽相关的核酸和多肽组合物以及相关的调节剂，例如抗体和小分子调节剂。本发明还提供了制备和使用这些多核苷酸，多肽，相关组合物和调节剂的方法。这些方法包括诊断，预防和治疗应用。本发明的组合物和方法可用于治疗增殖性病症，例如癌症以及炎症，免疫，细菌和病毒病症。

3. 发明申请

WO2006014999A3 COMPOSITIONS AND METHODS OF USE FOR MODULATORS OF NECTIN 4, SEMAPHORIN 4B, IGSF9, AND KIAA0152 IN TREATING DISEASE 审中-公开
标题翻译： NECTIN 4，SEMAPHORIN 4B，IGSF9和KIAA0152在治疗疾病中的调节剂的组合物和方法
公开(公告)号：WO2006014999A3
公开(公告)日：2006-12-21
申请号：PCT/US2005026561
申请日：2005-07-27
申请人： FIVE PRIME THERAPEUTICS INC , WONG JUSTIN , HESTIR KEVIN , LEE ERNESTINE
发明人： WONG JUSTIN , HESTIR KEVIN , LEE ERNESTINE
IPC分类号： C07K14/705 , A61K31/7088 , A61K38/17 , A61K39/395 , A61P35/00 , C07K16/28 , C12N5/10
CPC分类号： C07K14/4703
摘要： Microarray analysis, confirmed by RT-PCT, demonstrated that mRNA derived from cancerous tissues hybridized specifically and preferentially to human nectin 4, semaphorin 4b, IgSF9, and KIAA0152. Microarray analysis also demonstrated that RNA from malignant bladder, pancreas, and stomach tissue hybridized specifically to human nectin 4, semaphorin 4b, IgSF9, and KIAAO 152, all of which are transmembrane proteins that provide a therapeutic target for treating cancer. Modulators of nectin 4, semaphorin 4b, IgSF9, and KIAAO152 are provided for the diagnosis and treatment of proliferative disorders such as cancer and psoriasis. The invention further provides methods of treating cancer with therapeutic agents directed toward nectin 4, semaphorin 4b, IgSF9, and KIAAO152.
摘要翻译：通过RT-PCT证实的微阵列分析表明，衍生自癌组织的mRNA特异性地优先与人Nectin 4，信号素4b，IgSF9和KIAA0152杂交。微阵列分析还证明，来自恶性膀胱，胰腺和胃组织的RNA特异性与人Nectin 4，信号素4b，IgSF9和KIAAO 152杂交，所有这些都是提供治疗癌症的治疗靶标的跨膜蛋白。提供了Nectin4，semaphorin 4b，IgSF9和KIAAO152的调节剂用于诊断和治疗增殖性疾病如癌症和牛皮癣。本发明还提供了用于针对nectin4，semaphorin 4b，IgSF9和KIAAO152的治疗剂治疗癌症的方法。

4. 发明申请

WO2005066211A3 FIBROBLAST GROWTH FACTOR RECEPTORS 1, 2, 3, AND 4 AS TARGETS FOR THERAPEUTIC INTERVENTION 审中-公开
标题翻译：成纤维细胞生长因子受体1,2,3和4作为治疗干预的目标
公开(公告)号：WO2005066211A3
公开(公告)日：2005-11-03
申请号：PCT/US2004042163
申请日：2004-12-17
申请人： FIVE PRIME THERAPEUTICS INC , ZENG CHANGJIANG , HESTIR KEVIN , PIERCE KRISTEN , WILLIAMS LEWIS T , BOSCH ELIZABETH , MASUOKA LORIANNE , WONG JUSTIN G P , WANG YAN , CHU KETING , LEE ERNESTINE
发明人： ZENG CHANGJIANG , HESTIR KEVIN , PIERCE KRISTEN , WILLIAMS LEWIS T , BOSCH ELIZABETH , MASUOKA LORIANNE , WONG JUSTIN G P , WANG YAN , CHU KETING , LEE ERNESTINE
IPC分类号： C07K14/71 , C07K16/28 , C12Q1/68 , G01N33/574 , G01N33/74
CPC分类号： C07K16/2863 , C07K14/71 , G01N33/574 , G01N33/74 , G01N2333/50 , G01N2800/04 , G01N2800/065 , G01N2800/085 , G01N2800/102 , G01N2800/104 , G01N2800/105 , G01N2800/324
摘要： Isolated fibroblast growth factor receptor 1 ("FGFR1"), fibroblast growth factor receptor 2 ("FGFR2"), fibroblast growth factor receptor 3 ("FGFR3"), and fibroblast growth receptor 4 ("FGFR4") polypeptides and polynucleotides encoding the FGFR1-4 polypeptides, respectively, are provided. Additionally, antibodies, directed to the FGFR1-4 polypeptides and polynucleotides, inclusive of all polymorphic forms and variants thereof, are described. These antibodies either specifically activate the polypeptide or specifically interfere with the activity of the polypeptide. Further provided are methods of treating diseases, such as proliferative diseases, inflammatory diseases, and metabolic disorders, and kits and compositions employing the disclosed compositions. Specifically disclosed is a method of treating tumors in a subject where an antagonist of FGFR1, FGFR2, FGFR3, and/or FGFR4 is administered to the subject.
摘要翻译：分离的成纤维细胞生长因子受体1（“FGFR1”），成纤维细胞生长因子受体2（“FGFR2”），成纤维细胞生长因子受体3（“FGFR3”）和成纤维细胞生长受体4（“FGFR4”）多肽和编码FGFR1 -4多肽。另外，描述了针对FGFR1-4多肽和多核苷酸的抗体，包括所有的多态性形式和变体。这些抗体或者特异性激活多肽或者特异性干扰多肽的活性。进一步提供了治疗疾病例如增殖性疾病，炎症性疾病和代谢性疾病的方法，以及使用所公开的组合物的试剂盒和组合物。具体公开的是治疗受试者中施用FGFR1，FGFR2，FGFR3和/或FGFR4的拮抗剂的肿瘤的方法。

5. 发明申请

WO2007050798A3 LRRTM1 COMPOSITIONS AND METHODS OF THEIR USE FOR THE DIAGNOSIS AND TREATMENT OF CANCER 审中-公开
标题翻译： LRRTM1组合物及其用于癌症诊断和治疗的方法
公开(公告)号：WO2007050798A3
公开(公告)日：2007-11-15
申请号：PCT/US2006041852
申请日：2006-10-25
申请人： FIVE PRIME THERAPEUTICS INC , BOSCH ELIZABETH , HESTIR KEVIN , WONG JUSTIN
发明人： BOSCH ELIZABETH , HESTIR KEVIN , WONG JUSTIN
IPC分类号： C07K14/705 , A61K38/16 , A61K39/395 , C07K16/18 , C12N1/15 , C12N1/21 , C12N5/10 , G01N33/48 , G01N33/50
CPC分类号： C07K14/705 , A61K38/00
摘要： Microarray analysis, confirmed by RT-PCR, demonstrated that mRNA from certain cancer tissues, for example, ovarian cancer tissue, pancreatic cancer tissue, and colorectal cancer tissue, hybridizes specifically and preferentially to LRRTM1. LRRTM1 is a leucine-rich repeat transmembrane protein overexpressed on the surface of cancer cells compared to normal tissues and thus provides a therapeutic target for treating cancer. Modulators of LRRTM1, highly expressed in cancerous as compared to normal tissues, are provided for the diagnosis and treatment of proliferative disorders such as cancer. The invention further provides methods of treating cancer with therapeutic agents directed toward LRRTM1.
摘要翻译：通过RT-PCR证实的微阵列分析证实，来自某些癌症组织例如卵巢癌组织，胰腺癌组织和结直肠癌组织的mRNA特异性且优先与LRRTM1杂交。 LRRTM1是与正常组织相比在癌细胞表面过表达的富含亮氨酸的重复跨膜蛋白，因此提供了治疗癌症的治疗靶点。与正常组织相比，在癌症中高度表达的LRRTM1调节剂可用于增殖性疾病如癌症的诊断和治疗。本发明还提供了用针对LRRTM1的治疗剂治疗癌症的方法。

6. 发明申请

WO2006124013A2 NOVEL STROMAL CELL-DERIVED FACTOR-1 POLYPEPTIDES, POLYNUCLEOTIDES, MODULATORS THEREOF, AND METHOD OF USE 审中-公开
标题翻译：新型结晶细胞衍生因子-1多肽，多核苷酸，调节因子及其使用方法
公开(公告)号：WO2006124013A2
公开(公告)日：2006-11-23
申请号：PCT/US2005014963
申请日：2005-04-29
申请人： FIVE PRIME THERAPEUTICS INC , CHU KETING , WILLIAMS LEWIS T , WONG JUSTIN G P , HESTIR KEVIN , COLLINS AMY L TSUI , LEE ERNESTINE
发明人： CHU KETING , WILLIAMS LEWIS T , WONG JUSTIN G P , HESTIR KEVIN , COLLINS AMY L TSUI , LEE ERNESTINE
CPC分类号： C07K14/522 , Y10T436/143333
摘要： Disclosed herein is a newly identified SDF-1 splice variant molecule, its polypeptide sequence, and the polynucleotides encoding the polypeptide sequence, and active fragments thereof. Also provided is a procedure for producing such polypeptides by recombinant techniques e4mploying, for example, vectors and host cells. Also disclosed are methods for utilizing such polypeptides modulators thereof for the treatment of diseases, including cancer, immune diseases, infectious diseases, and ischemic diseases.
摘要翻译：本文公开了新鉴定的SDF-1剪接变体分子，其多肽序列和编码多肽序列的多核苷酸及其活性片段。还提供了通过使用例如载体和宿主细胞的重组技术产生这种多肽的方法。还公开了利用其多肽调节剂用于治疗疾病（包括癌症，免疫疾病，感染性疾病和缺血性疾病）的方法。

7. 发明申请

WO2007014123A3 COMPOSITIONS AND METHODS OF TREATING DISEASE WITH FGFR FUSION PROTEINS 审中-公开
标题翻译：用FGFR融合蛋白治疗疾病的组合物和方法
公开(公告)号：WO2007014123A3
公开(公告)日：2007-11-15
申请号：PCT/US2006028597
申请日：2006-07-24
申请人： FIVE PRIME THERAPEUTICS INC , WILLIAMS LEWIS T , BOSCH ELIZABETH , DOBERSTEIN STEPHEN , HESTIR KEVIN , HOLLENBAUGH DIANE , LEE ERNESTINE , QIN MINMIN , SADRA ALI , WONG JUSTIN , WU GE , ZHANG HONGBING
发明人： WILLIAMS LEWIS T , BOSCH ELIZABETH , DOBERSTEIN STEPHEN , HESTIR KEVIN , HOLLENBAUGH DIANE , LEE ERNESTINE , QIN MINMIN , SADRA ALI , WONG JUSTIN , WU GE , ZHANG HONGBING
IPC分类号： C12N15/62 , C07K14/71
CPC分类号： C07K14/71 , A61K45/06 , C07K14/765 , C07K16/2863 , C07K17/08 , C07K2319/30 , C07K2319/32
摘要： The invention provides FGFR fusion proteins, methods of making them, and methods of using them to treat proliferative disorders, including cancers and disorders of angiogenesis. The FGFR fusion molecules can be made in CHO cells and may comprise deletion mutations in the extracellular domains of the FGFRs which improve their stability. These fusion proteins inhibit the growth and viability of cancer cells in vitro and in vivo. The combination of the relatively high affinity of these receptors for their ligand FGFs and the demonstrated ability of these decoy receptors to inhibit tumor growth is an indication of the clinical value of the compositions and methods provided herein.
摘要翻译：本发明提供了FGFR融合蛋白，其制备方法以及使用它们来治疗增殖性疾病（包括癌症和血管生成障碍）的方法。 FGFR融合分子可以在CHO细胞中制备，并且可以包含改善其稳定性的FGFRs的细胞外结构域中的缺失突变。这些融合蛋白体外和体内抑制癌细胞的生长和活力。这些受体对其配体FGF的相对高亲和力的组合以及这些诱饵受体抑制肿瘤生长的证明的能力是本文提供的组合物和方法的临床价值的指示。

8. 发明申请

WO2007098093A2 COMPOSITIONS AND METHODS OF USE FOR MODULATORS OF POLYPEPTIDES AND POLYNUCLEOTIDES IN TREATING BREAST CANCER AND MELANOMA 审中-公开
标题翻译：多肽和多核苷酸调节剂在治疗乳腺癌和梅毒中的组合物和方法
公开(公告)号：WO2007098093A2
公开(公告)日：2007-08-30
申请号：PCT/US2007004255
申请日：2007-02-20
申请人： FIVE PRIME THERAPEUTICS INC , HESTIR KEVIN , WONG JUSTIN
发明人： HESTIR KEVIN , WONG JUSTIN
IPC分类号： A61K39/00
CPC分类号： C07K14/47 , A61K38/00
摘要： This invention relates to the polynucleotides and the encoded polypeptides, including novel sequences, of human or non-human primate genes that are amplified in breast and/or other tumor tissues melanoma, as compared to the corresponding normal tissue. The invention also relates to modulators of such polynucleotides and polypeptides, for example, antibodies, that specifically bind to and/or interfere with the activity of this polypeptide, polynucleotide, its fragments, variants, and antagonists. The invention further relates to compositions containing such a polypeptide, polynucleotide, or modulators thereof and uses of such compositions in methods of treating or preventing cancer, by detecting this polynucleotide, polypeptide, or antibodies thereto in patient samples. The invention also provides diagnostic tests for breast cancer and melanoma, by identifying polypeptides and polynucleotides encoded by the cDNA sequence of the invention that correlate with those disorders.
摘要翻译：本发明涉及与相应的正常组织相比，在乳腺和/或其它肿瘤组织黑素瘤中扩增的人或非人灵长类动物基因的多核苷酸和编码多肽，包括新的序列。本发明还涉及这种多核苷酸和多肽的调节剂，例如抗体，其特异性结合和/或干扰该多肽，多核苷酸，其片段，变体和拮抗剂的活性。本发明还涉及含有这种多肽，多核苷酸或其调节剂的组合物以及通过在患者样品中检测该多核苷酸，多肽或其抗体来治疗或预防癌症的方法中的这种组合物的用途。本发明还通过鉴定与本发明的cDNA序列编码的多肽和与这些疾病相关的多核苷酸来提供乳腺癌和黑素瘤的诊断测试。

9. 发明申请

WO2005035569A3 KIAA0779, SPLICE VARIANTS THEREOF, AND METHODS OF THEIR USE 审中-公开
标题翻译： KIAA0779，其SPLICE变体及其使用方法
公开(公告)号：WO2005035569A3
公开(公告)日：2006-03-02
申请号：PCT/US2004033408
申请日：2004-10-12
申请人： FIVE PRIME THERAPEUTICS INC , WONG JUSTIN G P , HESTIR KEVIN , COLLINS AMY L TSUI
发明人： WONG JUSTIN G P , HESTIR KEVIN , COLLINS AMY L TSUI
IPC分类号： C07K14/47 , C07K14/705
CPC分类号： C07K14/705
摘要： The invention provides novel polynucleotides, related polypeptides related nucleic acid and polypeptide compositions, and related modulators, such as antibodies and small molecule modulators. The invention also provides methods to make and use these polynucleotides, polypeptides, related compositions, and modulators. These methods include diagnostic, prophylactic, and therapeutic applications. The compositions and methods of the invention are useful in treating proliferative disorders, e.g., cancers, such as kidney and pancreatic cancer; and inflammatory, immune, and viral disorders.
摘要翻译：本发明提供新的多核苷酸，相关多肽相关的核酸和多肽组合物以及相关的调节剂，例如抗体和小分子调节剂。本发明还提供了制备和使用这些多核苷酸，多肽，相关组合物和调节剂的方法。这些方法包括诊断，预防和治疗应用。本发明的组合物和方法可用于治疗增殖性疾病，例如癌症，例如肾脏和胰腺癌; 和炎性，免疫和病毒性疾病。

10. 发明申请

WO2006014903A2 COMPOSITIONS AND METHODS OF USE FOR ADAM12 ANTAGONISTS IN TREATING DISEASE 审中-公开
标题翻译：用于ADAM12拮抗剂治疗疾病的组合物和方法
公开(公告)号：WO2006014903A2
公开(公告)日：2006-02-09
申请号：PCT/US2005026402
申请日：2005-07-26
申请人： FIVE PRIME THERAPEUTICS INC , BOSCH ELIZABETH , HESTIR KEVIN , LEE ERNESTINE , LIN HAISHAN , WONG JUSTIN
发明人： BOSCH ELIZABETH , HESTIR KEVIN , LEE ERNESTINE , LIN HAISHAN , WONG JUSTIN
IPC分类号： C12Q1/68 , A61K31/7088 , A61K39/395 , A61P35/00 , C07K16/28 , C12N5/10
CPC分类号： G01N33/574 , C12Q1/6886 , C12Q2600/136 , G01N2333/96486
摘要： Microarray analysis, confirmed by RT-PCT, demonstrated that lung squamous cell carcinoma, colon/colorectal cancer, and breast carcinoma mRNA hybridizes specifically and preferentially to ADAM12L. Microarray analysis also demonstrated that RNA from malignant bladder, pancreas, and stomach tissue hybridizes specifically to ADAM12. ADAM12L is a transmembrane protein overexpressed on the surface of cancer cells compared to normal tissues and thus provides a therapeutic target for treating cancer. Modulators of ADAM12, highly expressed in cancerous as compared to normal tissues, are provided for the diagnosis and treatment of proliferative disorders such as cancer and psoriasis. The invention further provides methods of treating cancer with therapeutic agents directed toward ADAM12.
摘要翻译：通过RT-PCT证实的微阵列分析证实肺鳞状细胞癌，结肠/结肠直肠癌和乳腺癌mRNA特异性杂交并优先与ADAM12L杂交。微阵列分析还表明来自恶性膀胱，胰腺和胃组织的RNA与ADAM12特异性杂交。 ADAM12L是一种与正常组织相比在癌细胞表面过表达的跨膜蛋白，因此为治疗癌症提供了治疗靶点。与正常组织相比，癌性高表达的ADAM12调节剂可用于增殖性疾病如癌症和银屑病的诊断和治疗。本发明进一步提供了用针对ADAM12的治疗剂治疗癌症的方法。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式